Target protein degradation by protacs: A budding cancer treatment strategy.

[1]  Yuzhan Li,et al.  Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design. , 2023, European journal of medicinal chemistry.

[2]  H. Ran,et al.  Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death. , 2023, Journal of medicinal chemistry.

[3]  E. Ruppin,et al.  Ubiquitin ligases Siah1a/2 control alveolar macrophage functions to limit carcinogen-induced lung adenocarcinoma. , 2023, Cancer research.

[4]  Jian Xiao,et al.  Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines. , 2023, European journal of medicinal chemistry.

[5]  Jiajia Chen,et al.  BRD4: New Hope in the Battle Against Glioblastoma. , 2023, Pharmacological research.

[6]  Nanxin Liu,et al.  Discovery of novel PROTACs based on multi-targeted angiogenesis inhibitors. , 2023, Bioorganic & medicinal chemistry letters.

[7]  Yi Liu,et al.  Application of PROTACs in the Pharmaceutical Direction , 2023, International Journal of Biology and Life Sciences.

[8]  Navnath S. Gavande,et al.  PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy , 2023, Molecular Cancer.

[9]  Xiaoyan Pan,et al.  Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance. , 2023, Pharmacology & therapeutics.

[10]  Suhua Wang,et al.  Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands. , 2023, Bioorganic & medicinal chemistry.

[11]  Aiping Lu,et al.  Targeted protein degradation in cancers: Orthodox PROTACs and beyond. , 2023, Innovation (Cambridge (Mass.)).

[12]  Chengxiao Fu,et al.  The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapy , 2023, Cancer.

[13]  G. Collie,et al.  E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology , 2023, Journal of medicinal chemistry.

[14]  Yanmin Zhang,et al.  Recent advances in targeted protein degraders as potential therapeutic agents , 2023, Molecular diversity.

[15]  C. Crews,et al.  Protein degraders enter the clinic — a new approach to cancer therapy , 2023, Nature Reviews Clinical Oncology.

[16]  R. Drozda,et al.  PD-1/PD-L1 and DNA Damage Response in Cancer , 2023, Cells.

[17]  W. Cui,et al.  Recent advances in long-acting drug delivery systems for anticancer drug. , 2023, Advanced drug delivery reviews.

[18]  H. Cai,et al.  PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities , 2023, Molecules.

[19]  Xueqing Wu,et al.  Krüppel-like factors in tumors: Key regulators and therapeutic avenues , 2023, Frontiers in Oncology.

[20]  E. Nice,et al.  Protein degradation: expanding the toolbox to restrain cancer drug resistance , 2023, Journal of Hematology & Oncology.

[21]  C. Day,et al.  From seeds to trees: how E2 enzymes grow ubiquitin chains , 2023, Biochemical Society transactions.

[22]  Jinghong Li,et al.  Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors. , 2022, Journal of the American Chemical Society.

[23]  Mong-Hong Lee,et al.  CSN6 mediates nucleotide metabolism to promote tumor development and chemoresistance in colorectal cancer. , 2022, Cancer research.

[24]  Xin Han,et al.  Targeting androgen receptor degradation with PROTACs from bench to bedside. , 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[25]  B. Xing,et al.  Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras , 2022, Science advances.

[26]  Y. Shao,et al.  Design, synthesis, and biological evaluation of BRD4 degraders. , 2022, Bioorganic & medicinal chemistry.

[27]  Iris Z. Uras,et al.  Targeted Protein Degradation: Clinical Advances in the Field of Oncology , 2022, International journal of molecular sciences.

[28]  Hae-Seul Choi,et al.  Deubiquitinating Enzyme USP12 Regulates the Pro-Apoptosis Protein Bax , 2022, International journal of molecular sciences.

[29]  B. Schulman,et al.  An expanded lexicon for the ubiquitin code , 2022, Nature Reviews Molecular Cell Biology.

[30]  Xuejiao Han,et al.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies , 2022, Journal of Hematology & Oncology.

[31]  Arvind Negi,et al.  Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications , 2022, Applied Sciences.

[32]  K. Dua,et al.  PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras , 2022, BioDrugs.

[33]  A. Vadukoot.  PROTACs: Opportunities and Challenges Ahead in the Field of Drug Discovery , 2022, International Journal of Medicine and Public Health.

[34]  T. Cunha-Oliveira,et al.  NRF2 and Mitochondrial Function in Cancer and Cancer Stem Cells , 2022, Cells.

[35]  H. Graham.  The mechanism of action and clinical value of PROTACs: A graphical review. , 2022, Cellular signalling.

[36]  Wanbo Li,et al.  UBE2G1 Is a Critical Component of Immune Response to the Infection of Pseudomonas Plecoglossicida in Large Yellow Croaker (Larimichthys crocea) , 2022, International journal of molecular sciences.

[37]  L. Ouyang,et al.  Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential. , 2022, Journal of medicinal chemistry.

[38]  A. Vertegaal.  Signalling mechanisms and cellular functions of SUMO , 2022, Nature Reviews Molecular Cell Biology.

[39]  Dongming Xing,et al.  PROTACs for BRDs proteins in cancer therapy: a review , 2022, Journal of enzyme inhibition and medicinal chemistry.

[40]  Xiuyun Sun,et al.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021) , 2022, Signal Transduction and Targeted Therapy.

[41]  C. Crews,et al.  PROTACs: past, present and future. , 2022, Chemical Society reviews.

[42]  A. Ferlin,et al.  Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening , 2022, International journal of molecular sciences.

[43]  Qiaojun He,et al.  Deubiquitinating enzymes: promising targets for drug resistance. , 2022, Drug discovery today.

[44]  Li Ma,et al.  Monoubiquitination in Homeostasis and Cancer , 2022, International journal of molecular sciences.

[45]  Tamás Csizmadia,et al.  The role of K63-linked polyubiquitin in several types of autophagy , 2022, Biologia Futura.

[46]  C. Kho,et al.  Ubiquitin and Ubiquitin-like Proteins in Cancer, Neurodegenerative Disorders, and Heart Diseases , 2022, International journal of molecular sciences.

[47]  Ruiyao Mai,et al.  Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy. , 2022, Journal of medicinal chemistry.

[48]  M. Robles-Flores,et al.  An approach to p32/gC1qR/HABP1: a multifunctional protein with an essential role in cancer , 2022, Journal of Cancer Research and Clinical Oncology.

[49]  Wenchen Pu,et al.  Proteolysis-targeting chimeras (PROTACs) in cancer therapy , 2022, Molecular Cancer.

[50]  A. Tong,et al.  Targeted protein degradation: mechanisms, strategies and application , 2022, Signal Transduction and Targeted Therapy.

[51]  Yangqiu Li,et al.  Anticancer effects of disulfiram in T‐cell malignancies through NPL4‐mediated ubiquitin–proteasome pathway , 2022, Journal of leukocyte biology.

[52]  C. Alonso-Moreno,et al.  Clinical considerations for the design of PROTACs in cancer , 2022, Molecular cancer.

[53]  R. González-Prieto,et al.  Insights in Post-Translational Modifications: Ubiquitin and SUMO , 2022, International journal of molecular sciences.

[54]  Rui Zhang,et al.  Ubiquitination/de-ubiquitination: A promising therapeutic target for PTEN reactivation in cancer. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[55]  Hong-Tao Zhang,et al.  RNA-binding Proteins and Cancer Metastasis. , 2022, Seminars in cancer biology.

[56]  Sarah Poliquin,et al.  Disruption of the Ubiquitin-Proteasome System and Elevated Endoplasmic Reticulum Stress in Epilepsy , 2022, Biomedicines.

[57]  Y. Kwon,et al.  The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system , 2022, Nature communications.

[58]  I. Sumara,et al.  Non-proteolytic ubiquitylation in cellular signaling and human disease , 2022, Communications Biology.

[59]  S. Desai,et al.  ISG15 and ISGylation in Human Diseases , 2022, Cells.

[60]  E. Robertson,et al.  The Central Role of the Ubiquitin–Proteasome System in EBV-Mediated Oncogenesis , 2022, Cancers.

[61]  D. Langley,et al.  PROTAC targeted protein degraders: the past is prologue , 2022, Nature Reviews Drug Discovery.

[62]  I. Mozgová,et al.  Polycomb Repressive Complex 2 in Eukaryotes—An Evolutionary Perspective , 2022, Epigenomes.

[63]  E. Tsiambas,et al.  Impact of Ubiquitination Signaling Pathway Modifications on Oral Carcinoma. , 2022, Cancer diagnosis & prognosis.

[64]  J. L. Ding,et al.  E2-E3 ubiquitin enzyme pairing - partnership in provoking or mitigating cancers. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[65]  D. Longley,et al.  The role of Ubiquitination in Apoptosis and Necroptosis , 2021, Cell Death & Differentiation.

[66]  Valentyn Oksenych,et al.  Acetyltransferases GCN5 and PCAF Are Required for B Lymphocyte Maturation in Mice , 2021, bioRxiv.

[67]  Jianhua Xu,et al.  Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer. , 2021, European journal of medicinal chemistry.

[68]  Shaomeng Wang,et al.  Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. , 2021, Journal of medicinal chemistry.

[69]  X. Yao,et al.  Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR , 2021, Acta pharmaceutica Sinica. B.

[70]  Jindan Yu,et al.  Going beyond Polycomb: EZH2 Functions in Prostate Cancer , 2021, Oncogene.

[71]  Wenyi Wei,et al.  Cell cycle on the crossroad of tumorigenesis and cancer therapy. , 2021, Trends in cell biology.

[72]  M. Pagano,et al.  Ubiquitin ligases in cancer: functions and clinical potentials. , 2021, Cell chemical biology.

[73]  Ivan Đikić,et al.  Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation. , 2021, Cell chemical biology.

[74]  Yongheng Chen,et al.  Targeting MCL-1 in cancer: current status and perspectives , 2021, Journal of Hematology & Oncology.

[75]  Rajwinder Kaur,et al.  PROTACs: A Hope for Breast Cancer Patients? , 2021, Anti-cancer agents in medicinal chemistry.

[76]  Manjinder Singh,et al.  PROTACs in Treatment of Cancer: A review. , 2021, Mini reviews in medicinal chemistry.

[77]  C. Blattner,et al.  Regulation of p53 by E3s , 2021, Cancers.

[78]  V. D’Angiolella,et al.  The role of E3 ubiquitin ligases in the development and progression of glioblastoma , 2021, Cell Death & Differentiation.

[79]  Rajwinder Kaur,et al.  Focus on the Multimodal Role of Biomarkers in Breast Cancer. , 2021, Current pharmaceutical design.

[80]  A. Bah,et al.  Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT , 2020, Frontiers in Immunology.

[81]  Xiangshu Xiao,et al.  PROTACs to address the challenges facing small molecule inhibitors. , 2020, European journal of medicinal chemistry.

[82]  B. Schulman,et al.  NEDD8 and ubiquitin ligation by cullin-RING E3 ligases. , 2020, Current opinion in structural biology.

[83]  M. Baud,et al.  Current strategies for the design of PROTAC linkers: a critical review , 2020, Exploration of targeted anti-tumor therapy.

[84]  Xu Peng,et al.  KEAP1 Mutations Drive Tumorigenesis by Suppressing SOX9 Ubiquitination and Degradation , 2020, Advanced science.

[85]  A. Pandiella,et al.  Proteolysis targeting chimeras (PROTACs) in cancer therapy , 2020, Journal of Experimental & Clinical Cancer Research.

[86]  Mohammed A. Alsahli,et al.  Expression and Correlation of Cell-Free cIAP-1 and cIAP-2 mRNA in Breast Cancer Patients: A Study from India , 2020, Journal of oncology.

[87]  S. Bañuelos,et al.  Nucleophosmin, a multifunctional nucleolar organizer with a role in DNA repair. , 2020, Biochimica et biophysica acta. Proteins and proteomics.

[88]  C. Crews,et al.  PROTACs: An Emerging Therapeutic Modality in Precision Medicine. , 2020, Cell chemical biology.

[89]  R. Hromas,et al.  Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies , 2020, Journal of Hematology & Oncology.

[90]  Qingzhong Hu,et al.  Chimera induced protein degradation: PROTACs and beyond. , 2020, European journal of medicinal chemistry.

[91]  Li‐Ping Sun,et al.  PROTAC: A promising technology for cancer treatment. , 2020, European journal of medicinal chemistry.

[92]  Guangming Zhou,et al.  SMAD-6, −7 and −9 are potential molecular biomarkers for the prognosis in human lung cancer , 2020, Oncology letters.

[93]  J. Qi,et al.  Peptide-Based PROTAC: The Predator of Pathological Proteins. , 2020, Cell chemical biology.

[94]  A. Italiano,et al.  Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors , 2020, Cancers.

[95]  A. Bishayee,et al.  Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy , 2020, Cells.

[96]  Yongcheng Song,et al.  Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy , 2020, Journal of Hematology & Oncology.

[97]  Daria Kotlarek,et al.  Targeted Protein Degradation: "The Gold Rush is On!" , 2020, Technology Transfer and Entrepreneurship.

[98]  Yu Ding,et al.  Emerging New Concepts of Degrader Technologies , 2020, Trends in Pharmacological Sciences.

[99]  Tingting Liu,et al.  Small-molecule PROTACs: novel agents for cancer therapy. , 2020, Future medicinal chemistry.

[100]  Shigui Li,et al.  The Ubiquitin Conjugating Enzyme: An Important Ubiquitin Transfer Platform in Ubiquitin-Proteasome System , 2020, International journal of molecular sciences.

[101]  W. Sippl,et al.  Proteolysis targeting chimeras (PROTACs) for epigenetics research. , 2020, Current opinion in chemical biology.

[102]  Wenyi Wei,et al.  The role of ubiquitination in tumorigenesis and targeted drug discovery , 2020, Signal Transduction and Targeted Therapy.

[103]  M. Naito,et al.  Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety , 2020, Pharmaceuticals.

[104]  K. Javed,et al.  Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges , 2020, Genetics and molecular biology.

[105]  R. Deshaies,et al.  Harnessing the Power of Proteolysis for Targeted Protein Inactivation. , 2020, Molecular cell.

[106]  G. Winter,et al.  Expanding the Degradable Proteome: Designing PROTACs by the Book. , 2020, Cell chemical biology.

[107]  C. Pritchard,et al.  Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery , 2020, British Journal of Cancer.

[108]  Juan Ye,et al.  GSTpi regulates VE-cadherin stabilization through promoting S-glutathionylation of Src , 2019, Redox biology.

[109]  Y. Shiloh,et al.  The Role of E3, E4 Ubiquitin Ligase (UBE4B) in Human Pathologies , 2019, Cancers.

[110]  A. Ciulli.  Targeted Protein Degradation with Small Molecules: How PROTACs Work , 2019, Proceedings.

[111]  M. Naito,et al.  Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs , 2019, Front. Chem..

[112]  Xiuyun Sun,et al.  PROTACs: great opportunities for academia and industry , 2019, Signal Transduction and Targeted Therapy.

[113]  A. Toker,et al.  Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling , 2019, bioRxiv.

[114]  Shao-Cong Sun,et al.  TBKBP1 and TBK1 form a growth factor signaling axis mediating immunosuppression and tumorigenesis , 2019, Nature Cell Biology.

[115]  Ming-Ming Zhou,et al.  Bromodomain biology and drug discovery , 2019, Nature Structural & Molecular Biology.

[116]  Matthieu Schapira,et al.  Targeted protein degradation: expanding the toolbox , 2019, Nature Reviews Drug Discovery.

[117]  Alexander Dömling,et al.  PROTACs– a game-changing technology , 2019, Expert opinion on drug discovery.

[118]  Philip P. Chamberlain,et al.  Development of targeted protein degradation therapeutics , 2019, Nature Chemical Biology.

[119]  Yang Wang,et al.  Degradation of proteins by PROTACs and other strategies , 2019, Acta pharmaceutica Sinica. B.

[120]  Y. Duan,et al.  The Present and Future of Novel Protein Degradation Technology. , 2019, Current topics in medicinal chemistry.

[121]  G. Cottrell,et al.  Toll-like receptor 4 and protease-activated receptor 2 in physiology and pathophysiology of the nervous system: more than just receptor cooperation? , 2019, Neural regeneration research.

[122]  Han-Qing Zhu,et al.  Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation , 2019, Journal of Cancer.

[123]  C. Crews,et al.  Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs) , 2019, ACS central science.

[124]  P. Vijay,et al.  Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes , 2019, Molecular Cancer Therapeutics.

[125]  C. Crews,et al.  Targeted protein degradation: elements of PROTAC design. , 2019, Current opinion in chemical biology.

[126]  A. Ciulli,et al.  Protein degradation for drug discovery. , 2019, Drug discovery today. Technologies.

[127]  C. Crews,et al.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. , 2019, Drug discovery today. Technologies.

[128]  C. Loh,et al.  Targeted protein degradation mechanisms. , 2019, Drug discovery today. Technologies.

[129]  A. Gamper,et al.  Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis , 2019, The Journal of clinical investigation.

[130]  H. Jang.  Regulation of Protein Degradation by Proteasomes in Cancer , 2018, Journal of cancer prevention.

[131]  Michiel van Gent,et al.  TRIM Proteins and Their Roles in Antiviral Host Defenses. , 2018, Annual review of virology.

[132]  R. Roden,et al.  Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer , 2018, ACS omega.

[133]  Jane A. Endicott,et al.  Structural insights into the functional diversity of the CDK–cyclin family , 2018, Open Biology.

[134]  Qi Tang,et al.  Pleiotropic roles of the ubiquitin-proteasome system during viral propagation , 2018, Life Sciences.

[135]  Pingyuan Wang,et al.  Proteolysis Targeting Chimera (PROTAC): A Paradigm-Shifting Approach in Small Molecule Drug Discovery. , 2018, Current topics in medicinal chemistry.

[136]  Shanshan Gu,et al.  PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery , 2018, BioEssays : news and reviews in molecular, cellular and developmental biology.

[137]  Jianfei Qi,et al.  Ubiquitin ligases in oncogenic transformation and cancer therapy , 2017, Nature Reviews Cancer.

[138]  P. Workman,et al.  Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766) , 2017, Journal of medicinal chemistry.

[139]  D. Trisciuoglio,et al.  BCL-XL overexpression promotes tumor progression-associated properties , 2017, Cell Death & Disease.

[140]  Gerry Melino,et al.  Zinc-finger proteins in health and disease , 2017, Cell Death Discovery.

[141]  Jing Wang,et al.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. , 2017, Cell chemical biology.

[142]  A. Ciulli,et al.  Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders , 2017, Essays in biochemistry.

[143]  H. Cui,et al.  Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma , 2017, Oncotarget.

[144]  S. Safe,et al.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target , 2017, Archives of Toxicology.

[145]  Yingming Zhao,et al.  Phosphorylation of Pkp1 by RIPK4 regulates epidermal differentiation and skin tumorigenesis , 2017, The EMBO journal.

[146]  Wei-Guo Zhu,et al.  PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment , 2017, Autophagy.

[147]  Md Abu Shufean,et al.  ALK: a tyrosine kinase target for cancer therapy , 2017, Cold Spring Harbor molecular case studies.

[148]  T. Heightman,et al.  Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras , 2016, ACS central science.

[149]  Craig M. Crews,et al.  Induced protein degradation: an emerging drug discovery paradigm , 2016, Nature Reviews Drug Discovery.

[150]  R. Scarpulla,et al.  Concerted Action of PGC-1-related Coactivator (PRC) and c-MYC in the Stress Response to Mitochondrial Dysfunction* , 2016, The Journal of Biological Chemistry.

[151]  Kevin Kalinsky,et al.  AKT in cancer: new molecular insights and advances in drug development , 2016, British journal of clinical pharmacology.

[152]  Y. Huang,et al.  Hepatitis B virus X protein in liver tumor microenvironment , 2016, Tumor Biology.

[153]  J. Xiong,et al.  FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2 , 2016, Oncogene.

[154]  Jason Gertz,et al.  Cooperative Dynamics of AR and ER Activity in Breast Cancer , 2016, Molecular Cancer Research.

[155]  L. Ellis,et al.  HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma , 2016, BMC Cancer.

[156]  G. Crabtree,et al.  The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer. , 2016, Cold Spring Harbor perspectives in medicine.

[157]  M. Fratelli,et al.  RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells , 2016, Oncotarget.

[158]  D. Alkon,et al.  Protein Kinase Cϵ (PKCϵ) Promotes Synaptogenesis through Membrane Accumulation of the Postsynaptic Density Protein PSD-95* , 2016, The Journal of Biological Chemistry.

[159]  A. Redig,et al.  Targeting BET bromodomain proteins in solid tumors , 2016, Oncotarget.

[160]  J. Catravas,et al.  Hsp90 inhibition suppresses NF-κB transcriptional activation via Sirt-2 in human lung microvascular endothelial cells. , 2016, American journal of physiology. Lung cellular and molecular physiology.

[161]  A. Lichtenstein,et al.  SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism , 2016, Molecular Cancer Research.

[162]  C. Crews,et al.  Small-Molecule PROTACS: New Approaches to Protein Degradation. , 2016, Angewandte Chemie.

[163]  Jerson L. Silva,et al.  Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer , 2015, Front. Oncol..

[164]  J. Jones,et al.  The clinical and functional significance of c-Met in breast cancer: a review , 2015, Breast Cancer Research.

[165]  D. Schlaepfer,et al.  FAK in cancer: mechanistic findings and clinical applications , 2014, Nature Reviews Cancer.

[166]  H. Xu,et al.  Androgen receptor: structure, role in prostate cancer and drug discovery , 2014, Acta Pharmacologica Sinica.

[167]  G. Gores,et al.  Cellular Inhibitor of Apoptosis (cIAP)-Mediated Ubiquitination of Phosphofurin Acidic Cluster Sorting Protein 2 (PACS-2) Negatively Regulates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Cytotoxicity , 2014, PloS one.

[168]  Yi Sun,et al.  Targeting E3 Ubiquitin Ligases for Cancer Therapy , 2003, Cancer biology & therapy.

[169]  M. Affolter,et al.  A nutrigenomics view of protein intake: macronutrient, bioactive peptides, and protein turnover. , 2012, Progress in molecular biology and translational science.

[170]  K. Carmony,et al.  PROTAC-induced proteolytic targeting. , 2012, Methods in molecular biology.

[171]  Yaqin Tu,et al.  The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. , 2012, International journal of clinical and experimental pathology.

[172]  K. Sakamoto,et al.  Proteolysis Targeting Chimeric Molecules , 2009 .